Overview
Introducing SENTRY CLARITY, your in-office solution to the problem of common, questionable, head and neck lesions.
​
You can now reliably identify dysplastic lesions that can be effectively treated, potentially avoiding progression to HNSCC, and early-stage cancers when local therapy is effective in 95% of patients.
​
TM
About Sentry Laboratories
We are a state-of-the-art laboratory that specializes in the diagnosis of head and neck cancers and dysplasia.
We provide expedient and accurate diagnoses through Augmented Intelligence, integrating proprietary neural networks trained on tens of thousands of Head and Neck cases with experts in ENT pathology. This:
-
Increases diagnostic accuracy
-
Optimizes sensitivity and specificity through computer-assisted morphology and computer-assisted immunohistochemical testing
-
Minimizes pathologists' intra-observer and inter-observer variability
Our Analysis Process
ENT Specialty Laboratory
Your biopsy will be analyzed by the only laboratory that specializes in the diagnosis of Head and Neck cancers and their precursor lesions, dysplasia. All specimens are analyzed by experienced board-certified H&N specialist pathologists.
Neural Network Assisted Morphology for Accurate Disease Identification
Our artificial intelligence-based proprietary software uses neural networks specifically trained on tens of thousands of Head and Neck cases to identify dysplasia and SCC.
Computer-Assisted Molecular Adjunctive Testing
Sensitivity and specificity of computer-assisted morphology is further optimized through computer-assisted immunohistochemical testing of each specimen for HPV (p16) combined with abnormal tumor suppression and cell proliferation markers (p53 and Ki67).
Sentry Clarity Equals Diagnostic Precision
Our proprietary computer-assisted morphologic testing, immunohistochemical staining, and ENT specialty pathologists- all combined- provide you with the highest quality result.
When a precursor lesion is identified, dysplasia can be effectively treated,
potentially preventing HNSCC from ever developing.
A Simple Process. Powerful Results.
EASY TO IMPLEMENT
Biopsy specimen is obtained in the office and submitted to Sentry Labs for analysis via a supplied pre-paid return mailer.
ACTIONABLE DIAGNOSIS
Final pathology report is
prepared by expert pathologists with computer-assisted analysis
of specimens based upon morphological evidence and molecular markers.
​
HIGHLY ACCURATE RESULTS
High sensitivity and specificity provide an accurate diagnosis, thereby improving patient outcomes.
Providing Pathologic Results of Common Questionable Head and Neck Lesions
Common-appearing H&N lesions confirmed to be dysplastic or cancerous
Head and Neck Cancer Facts:​​
-
Cancer of the head and neck account for approximately 66,000 cases and 15,000 U.S. deaths annually, with an incidence that is anticipated to increase by 30% by 2030.
-
Risk factors for head and neck cancer include: tobacco and alcohol consumption, gastroesophageal reflux disease/laryngopharyngeal reflux, exposure to environmental pollutants and infection with viral agents (HPV and EBV).
-
The rate of HPV-related oropharyngeal cancer is increasing at a rate of 2.5% per year.
-
Despite the fact that HNSCC follows an ordered series of steps beginning with epithelial cell hyperplasia, followed by dysplasia (low grade, high grade), carcinoma in situ and, ultimately, invasive carcinoma, the majority of patients are diagnosed with late-stage disease (Stage III and IV).
-
When detected early, local therapy is effective in up to 95% of patients with early-stage HNSCC. When a precursor lesion is identified, dysplasia can be effectively treated, potentially preventing Head and Neck cancer from ever developing.